Rangwala Reshma 4
4 · Karyopharm Therapeutics Inc. · Filed Mar 4, 2024
Insider Transaction Report
Form 4
Rangwala Reshma
EVP & Chief Medical Officer
Transactions
- Sale
Common
2024-02-29$1.17/sh−15,667$18,330→ 355,689 total - Sale
Common
2024-03-01$1.20/sh−5,969$7,163→ 349,720 total
Footnotes (3)
- [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
- [F2]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person.